ArticleBiotechnology and applied biochemistry2026
Exploring Molecular Signature and Prognostic Biomarkers in Ovarian Cancer: Insights From Late-Stage, Recurrent, and Metastatic Tumors.
Article in Biotechnology and applied biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- EBF1 Deficiency Drives Prostate Cancer Progression by Interfering with the Transcriptional Regulation ofOncology research · 2026Article
- Profiling miRNA in salivary samples from subjects with endometriosis: a pilot study.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ovarian Cancer is a leading cause of mortality among women globally, primarily due to lack of specific and sensitive early-stage diagnostic tools. This study aims to identify hub genes associated with recurrent, late-stage, and metastatic tumors as potential prognostic biomarkers and drug targets. Gene expression data from eight National Center for Biotechnology Information (NCBI)-Gene Expression Omnibus (GEO) datasets were categorized by recurrence, tumor-stage, and metastasis. Differential gene expression and enrichment analyses were performed. Hub genes were identified by protein-protein interaction networks and validated by the University of Alabama at Birmingham Cancer Data Analysis Portal (UALCAN), GEPIA2, pROC, and Kaplan-Meier plotter databases. Genetic alterations, immune cell infiltration, miRNA prediction, and drug-gene interactions were assessed using cBioPortal, CIBERSORTx, Encyclopedia of RNA Interactomes (ENCORI), and Drug-Gene Interaction Database (DGIdb), respectively. Eight hub genes (FN1, COL1A1, COL1A2, COL3A1, POSTN, LUM, IGF1, and CXCL8) were identified, with COL1A2 common across all tumor categories. Note that 19.6% of cases showed mutations in these genes, primarily COL3A1. Overexpression of most hub genes and reduced expression of CXCL8 correlated with worse survival outcomes. COL1A1 and FN1 showed strong diagnostic ability. Late-stage tumors showed elevated M2 macrophages and neutrophils. hsa-miR-29a-3p, hsa-miR-29b-3p, and hsa-miR-29c-3p were identified as the most interactive miRNAs. Ocriplasmin and pamidronate were identified as potential therapeutics. Our findings highlight the therapeutic relevance of these hub genes and identify them as potential drug targets and prognostic biomarkers in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.